Fennec Pharmaceuticals is focused on addressing the significant issue of cisplatin-induced hearing loss in pediatric cancer patients. Cisplatin, a commonly used chemotherapy drug, is effective in treating various cancers but often leads to irreversible damage to the sensory hair cells in the inner ear, resulting in hearing loss. This condition is particularly concerning for young children, whose auditory systems are still developing, making them more susceptible to the ototoxic effects of the drug. The company emphasizes the importance of understanding the mechanisms behind this ototoxicity, which involves the production of reactive oxygen species that harm cochlear structures, leading to permanent hearing impairment and associated cognitive and social challenges.

To combat this pressing issue, Fennec Pharmaceuticals is dedicated to developing innovative treatments that can mitigate the risk of hearing loss associated with cisplatin therapy. Current interventions, such as hearing aids and cochlear implants, are often implemented after hearing loss has occurred and do not restore normal hearing. Fennec's approach aims to provide proactive solutions that address the unmet medical needs of children undergoing chemotherapy, thereby improving their quality of life and long-term outcomes. The company is committed to advancing research and development in this area, as evidenced by their participation in initiatives like the Patient Focused Drug Development meeting, which seeks to gather insights from affected patients and families to inform treatment strategies.

United States

Fennec Pharmaceuticals is a biotechnology company focused on improving the lives of children with cancer by addressing chemotherapy-induced hearing loss.

Fennec Pharma

Company Details